Management of neovascular age-related macular degeneration: Taiwan expert consensus

doi:10.1016/j.jfma.2021.06.012

中山醫學大學機構典藏 CSMUIR > 中山醫學大學研究成果 > 期刊論文 > Item 310902500/23802

Please use this identifier to cite or link to this item: https://ir.csmu.edu.tw:8080/ir/handle/310902500/23802

Title:	Management of neovascular age-related macular degeneration: Taiwan expert consensus
Authors:	Yeung, L;Hsieh, YT;Yang, CH;Chen, LJ;Chen, SJ;Cheng, CK;Sheu, SJ;Tsai, CY;Wu, TT;Wu, WC;Chen, SN
Keywords:	Neovascular age-related macular degeneration;Wet age-related macular degeneration;Vascular endothelial growth factors
Date:	2021
Issue Date:	2022-08-05T09:43:07Z (UTC)
Publisher:	ELSEVIER TAIWAN
ISSN:	0929-6646
Abstract:	Neovascular age-related macular degeneration (nAMD) is a leading cause of irreversible vision loss. The present consensus provides suggestions on diagnosis, evaluation, treatment, and follow-up strategies for nAMD from a panel of 11 practicing ophthalmologists. The experts suggest that the baseline visit for nAMD management should include a comprehensive ophthalmologic examination via a multimodal approach consisting of visual and anatomical evaluation. Patients diagnosed with nAMD should be subjected to treatment with the goal of maintaining visual function while diminishing anatomical disease activity and minimizing treatment burden. Currently, anti-VEGF therapy is the main treatment strategy for nAMD, and evaluation involving comprehensive ophthalmologic examination within 1 month of completion of the loading phase comprising three monthly injections is recommended to guide subsequent management. Either a treat-and-extend or pro re nata regimen can be considered for the maintenance phase of anti-VEGF therapy, and the regimen should be chosen and adjusted according to disease activity, reimbursement criteria, financial burden, and patient preferences. In the event of inactive nAMD or poor treatment outcomes, after thorough evaluation and patient education, anti-VEGF therapy may be stopped. The consensus provides practical nAMD management guidelines for ophthalmologists and fellow healthcare professionals. Copyright 2021, Formosan Medical Association. Published by Elsevier Taiwan LLC. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
URI:	http://dx.doi.org/10.1016/j.jfma.2021.06.012 https://www.webofscience.com/wos/woscc/full-record/WOS:000724839700003 https://ir.csmu.edu.tw:8080/handle/310902500/23802
Relation:	JOURNAL OF THE FORMOSAN MEDICAL ASSOCIATION ,2021,v120,issue 12, P2061-2071
Appears in Collections:	[中山醫學大學研究成果] 期刊論文

Files in This Item:

File	Description	Size	Format
index.html		0Kb	HTML	316	View/Open

Loading...